Drug Abuse and the Spread of Infection: HIV and AIDS as an Example

  • Don C. Des Jarlais
  • Holly Hagan
  • Samuel R. Friedman


Drug User Inject Drug User Methadone Maintenance Treatment Syringe Exchange Syringe Exchange Program 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Avants, S. K., Margolin, A., Usubiaga, M. H., and Doebrick, C. (2004). Targeting HIV-related outcomes with intravenous drug users maintained on methadone: A randomized clinical trial of a harm reduction group therapy. Journal of Substance Abuse Treatment 26(2), pp. 67–78.PubMedCrossRefGoogle Scholar
  2. Ball, A., Des Jarlais, D. C., Donoghoe, M., Friedman, S. R., Goldberg, D., Hunter, G. M., Stimson, G. V., and Wodak, A. (1994). Multi-Centre Study on Drug Injecting and Risk of HIV Infection: Geneva: World Health Organization, Programme on Substance Abuse.Google Scholar
  3. Blix, O. and Gronbladh, L. (1988). AIDS and IV Heroin Addicts: The Preventive Effect of Methadone Maintenance in Sweden. Paper presented at the Fourth International Conference on AIDS, Stockholm, Sweden.Google Scholar
  4. Bluthenthal, R., Kral, A., Lorvick, J., Erringer, E., and Edlin, B. (1998). Harm reduction and needle exchange programs. Lancet 351(9118), pp. 1819–1820.PubMedCrossRefGoogle Scholar
  5. Bluthenthal, R., Kral, A., Gee, L., Lorvick, J., Moore, L., Srol, K., and Edlin, B. (2001). Trends in HIV seroprevalence and risk among gay or bisexual men who inject drugs in San Francisco, 1998 to 2000. Journal of Acquired Immune Deficiency Syndrome 14, pp. 264–269.Google Scholar
  6. Braine, N., Des Jarlais, D. C., Zadoretzky, C., Goldblatt, C., and Turner, C. (Under review). HIV risk behavior among amphetamine injectors at US syringe exchange programs.Google Scholar
  7. Brettle, R. P. (1991). HIV and harm reduction for injection drug users. AIDS 5, pp. 125–136.PubMedCrossRefGoogle Scholar
  8. Broadhead, R. S., Heckathorn, D. D., Weakliem, D. L., Anthony, D. L., Madray, H., Mills, R. J., and Hughes, J. J. (1998). Harnessing peer networks as an instrument for AIDS prevention: Results from a peer driven intervention. Public Health Reports 113Suppl 1, pp. 42–57.PubMedGoogle Scholar
  9. Broers, B., Junet, C., Bourquin, M., Deglon, J. J., Perrin, L., & Hirschel, B. (1998). Prevalence and incidence of HIV, hepatitis B and C among drug users on methadone maintenance treatment in Geneva between 1988 and 1995. AIDS 12(15), pp. 2059–2066.PubMedGoogle Scholar
  10. Buning, E. C., Hartgers, C., Verster, A. D., van Santen, G. W., and Coutinho, R. A. (1988). The Evaluation of the Needle/Syringe Exchange in Amsterdam. Paper presented at the IV International Conference on AIDS, Stockholm, Sweden.Google Scholar
  11. Cartter, M. L., Petersen, L. R., Savage, R. B., and Donagher, J. (1990). Providing HIV counseling and testing services in methadone maintenance programs. AIDS 4(5), pp. 463–465.PubMedGoogle Scholar
  12. Chiasson, M. A., Stoneburner, R. L., Hildebrandt, D. S., Ewing, W. E., Telzak, E. E., and Jaffe, H. W. (1991). Heterosexual transmission of HIV-1 associated with the use of smokable freebase cocaine (crack). AIDS 5, pp. 1121–1126.PubMedGoogle Scholar
  13. Craib, K. J. P., Spittal, P. M., Wood, E., Laliberte, N., Hogg, R. S., Li, K., Heath, K., Tyndall, M. W., O’Shaughnessy, M. V., and Schechter, M. T. (2003). Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver. Canadian Medical Association Journal 168(1), pp. 19–24.PubMedGoogle Scholar
  14. Des Jarlais, D. C. (1995). Harm reduction—a framework for incorporating science into drug policy. American Journal of Public Health 85(1), pp. 10–12.PubMedGoogle Scholar
  15. Des Jarlais, D. C. (2002). The state of syringe exchange in the known universe. Paper presented at the 12th North American Syringe Exchange Convention, Albuquerque, NM.Google Scholar
  16. Des Jarlais, D. C. and Friedman, S. R. (1989). AIDS and IV Drug Use. Science 245, pp. 578–579.PubMedGoogle Scholar
  17. Des Jarlais, D. C. and Friedman, S. R. (1998). Fifteen years of research on preventing HIV infection among injecting drug users: What we have learned, what we have not learned, what we have done, what we have not done. Public Health Reports 113(Suppl 1), pp. 182–188.PubMedGoogle Scholar
  18. Des Jarlais, D. C., and Semaan, S. (2002). HIV prevention research: Cumulative knowledge or accumulating studies? Journal of Acquired Immune Deficiency Syndrome 30(Suppl 1), pp. S1–S7.Google Scholar
  19. Des Jarlais, D. C., and Shimizu, S. (2003). 2003 Evaluation Report: Hawaii Statewide Syringe Exchange Program. Honolulu: Chow (Community Health Outreach Work) Project.Google Scholar
  20. Des Jarlais, D. C., Friedman, S. R., and Hopkins, W. (1985). Risk reduction for the acquired immunodeficiency syndrome among intravenous drug users. Annals of Internal Medicine 103, pp. 755–759.PubMedGoogle Scholar
  21. Des Jarlais, D. C., Friedman, S. R., Novick, D., Sotheran, J. L., Thomas, P., Yancovitz, S., Mildvan, D., Weber, J., Kreek, M. J., Maslansky, R., Bartelme, S., Spira, T., and Marmor, M. (1989). HIV-l infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987. Journal of the American Medical Association 261, pp. 1008–1012.PubMedCrossRefGoogle Scholar
  22. Des Jarlais, D. C., Friedman, S. R., Choopanya, K., Vanichseni, S., and Ward, T. P. (1992). International epidemiology of HIV and AIDS among injecting drug users. AIDS 6, pp. 1053–1068.PubMedGoogle Scholar
  23. Des Jarlais, D. C., Friedman, S. R., and Ward, T. P. (1993). Harm reduction: A public health response to the AIDS epidemic among injecting drug users. Annual Review of Public Health 14, pp. 413–450.PubMedCrossRefGoogle Scholar
  24. Des Jarlais, D. C., Friedman, S. R., Sotheran, J. L., Wenston, J., Marmor, M., Yancovitz, S. R., Frank, B., Beatrice, S., and Mildvan, D. (1994). Continuity and change within an HIV epidemic: Injecting drug users in New York City, 1984 through 1992. Journal of the American Medical Association 271(2), pp. 121–127.PubMedCrossRefGoogle Scholar
  25. Des Jarlais, D., Hagan, H., Friedman, S., Friedman, P., Goldberg, D., Frischer, M., Green, S., Tunving, K., Ljungberg, B., Wodak, A., Ross, M., Purchase, D., Millson, M., and Myers, T. (1995). Maintaining low HIV seroprevalence in populations of injecting drug users. Journal of the American Medical Association 274(15), pp. 1226–1231.PubMedCrossRefGoogle Scholar
  26. Des Jarlais, D. C., Stimson, G. V., Hagan, H., Perlman, D., Choopanya, K., Bastos, F. I., and Friedman, S. R. (1996). Emerging infectious diseases and the injection of illicit psychoactive drugs. Current Issues in Public Health 2, pp.102–137.Google Scholar
  27. Des Jarlais, D. C., Perlis, T., Friedman, S. R., Deren, S., Chapman, T. F., Sotheran, J. L., Tortu, S., Beardsley, M., Paone, D., Torian, L.V., Beatrice, S. T., DeBernardo, E., Monterroso, E., and Marmor, M. (1998). Declining seroprevalence in a very large HIV epidemic: injecting drug users in New York City, 1991 to 1996. American Journal of Public Health 88(12), pp. 1801–1806.PubMedGoogle Scholar
  28. Des Jarlais, D. C., Hagan, H., and Friedman, S. R. (2004a). Epidemiology and emerging public health perspectives. In: Lowinson, J., Millman, R. B. and Ruiz, P. (Eds.), Substance Abuse: A Comprehensive Textbook 4e. Lippincott Williams & Wilkins, New York.Google Scholar
  29. Des Jarlais, D. C., Perlis, T., Arasteh, K., Hagan, H., Milliken, J., Braine, N., Yancovitz, S., Mildvan, D., Perlman, D., Maslow, C., and Friedman, S. R. (2004b). “Informed altruism” and “partner restriction” in the reduction of HIV infection in injecting drug users entering detoxification treatment in New York City, 1990–2001. Journal of Acquired Immune Deficiency Syndrome 35(2), pp. 158–166.CrossRefGoogle Scholar
  30. Des Jarlais, D. C., Perlis, T., Arasteh, K., Torian, L.V., Beatrice, S., Milliken, J., Mildvan, D., Yancovitz, S., and Friedman, S. R. (in press). STARHS testing for HIV incidence among injecting drug users in New York City, 1999–2002: Reduced incidence associated with expansion of syringe exchange programs. American Journal of Public Health.Google Scholar
  31. Drummond, M., Health Outcomes International PTY LTD and the National Centre for HIV Epidemiology and Clinical Research (2002). Return on Investment in Needle and Syringe Programs in Australia: Commonwealth Department of Health and Aging.Google Scholar
  32. Edlin, B. R., Irwin, K. L., and Faruque, S. (1994). Intersecting epidemics: Crack cocaine use and HIV infection among inner-city young adults. New England Journal of Medicine 331, pp. 1422–1427.PubMedCrossRefGoogle Scholar
  33. Espinoza, P., Bouchard, I., Ballian, P., and Polo DeVoto, J. (1988). Has the Open Sale of Syringes Modified the Syringe Exchanging Habits of Drug Addicts? Paper presented at the IV International Conference on AIDS, Stockholm, Sweden.Google Scholar
  34. European Centre for the Epidemiological Monitoring of AIDS. (1996). First Quarterly Report. World Health Organization, Geneva.Google Scholar
  35. European Centre for the Epidemiological Monitoring of AIDS. (2002). Annual report on the state of the drugs problem in the European Union and Norway. Luxembourg: European Monitoring Centre for Drugs and Drug Addiction.Google Scholar
  36. Friedman, S. R., Des Jarlais, D. C., Sotheran, J. L., Garber, J., Cohen, H., and Smith, D. (1987). AIDS and self-organization among intravenous drug users. International Journal of the Addictions 22, pp. 201–219.PubMedGoogle Scholar
  37. Friedman, S. R., Des Jarlais, D. C., and Ward, T. P. (1993). Overviewof the History of the HIV Epidemic among Drug Injectors. In: B. S. Brown, B.S., Beschner, G.M., and National AIDS Research Consortium (Eds.), Handbook on Risk of AIDS: Injection Drug Users and Sexual Partners, Greenwood Press, Westport, CT, pp. 3–15.Google Scholar
  38. Friedman, S. R., Jose, B., Neaigus, A., Goldstein, M., Curtis, R., Ildefonso, G., Mota, P., and Des jarlais, D.C. (1994). Consistent condom use in relationships between seropositive injecting drug users and sex partners who do not inject drugs. AIDS 8, pp. 357–361.PubMedGoogle Scholar
  39. Goldberg, D., Watson, H., Stuart, F., Miller, M., Gruer, L., and Follett, E. (1988). Pharmacy supply of needles and syringes-the effect on spread of HIV in intravenous drug misusers. Paper presented at the Fourth International Conference on AIDS, Stockholm, Sweden.Google Scholar
  40. Hagan, H., Des Jarlais, D. C., Friedman, S. R., Reid, T. R., & Bell, T. A. (1994). Risk of human immunodeficiency virus and hepatitis B virus in users of the Tacoma syringe exchange program, Proceedings of the National Academy of Sciences Workshop on Needle Exchange and Bleach Distribution Programs. National Academy Press, Washington, DC.Google Scholar
  41. Hankins, C., Alary, M., Parent, R., Blanchette, C., Claessens, C., and the SurvUDI Working Group. (2002). Continuing HIV transmission among injection drug users in Eastern Central Canada: The SurvUDI Study, 1995–2000. Journal of Acquired Immune Deficiency Syndrome 30, pp. 514–521.Google Scholar
  42. Heather, N., Wodak, A., Nadelmann, E., and O’Hare, P. (Eds.). (1993). Psychoactive Drugs and Harm Reduction: From Faith to Science. Whurr Publishers, London.Google Scholar
  43. Heimer, R., and Singer, M. (2003). Syringe Access, Use, and Discard—The I-91 Study. Paper presented at the National Development and Research Institutes, New York.Google Scholar
  44. Higgins, D. L., Galavotti, C., O’Reilly, K. R., Schnell, D. J., Moore, M., Rugg, D. L., and Johnson, R. (1991). Evidence for the effects of HIV antibody counseling and testing on risk behaviors. Journal of the American Medical Association 266, pp. 2419–2429.PubMedCrossRefGoogle Scholar
  45. Jackson, J., and Rotkiewicz, L. (1987). A Coupon Program: AIDS Education and Drug Treatment. Paper presented at the Third International Conference on AIDS, Washington, D.C.Google Scholar
  46. Jacquez, J., Koopman, J., Simon, C., and Longini, I. (1994). Role of the primary infection in epidemic HIV infection of gay cohorts. Journal of Acquired Immune Syndrome 7, pp. 1169–1184.Google Scholar
  47. Latkin, C. (1998). Outreach in natural settings: The use of peer leaders for HIV prevention among injection drug users’ networks. Public Health Reports 113, pp. 151–159.PubMedGoogle Scholar
  48. Latkin, C. A., Sherman, S., and Knowlton, A. (2003). HIV prevention among drug users: outcome of a network-oriented peer outreach intervention. Health Psychology 22(4), pp. 332–339.PubMedCrossRefGoogle Scholar
  49. Laumann, E., Gagnon, J. H., Michael, R., and Michaels, S. (1994). The Social Organization of Sexuality: Sexual Practices in the United States. University of Chicago Press, Chicago.Google Scholar
  50. Mackay, J. L. (1994). The fight against tobacco in developing countries. Tuberculosis and Lung Diseases 75, pp. 8–24.CrossRefGoogle Scholar
  51. Manipur State AIDS Control Society. (2002). HIV Sentinel Surveillance. Impal, India: Manipur State AIDS Control Society.Google Scholar
  52. Mann, J., Tarantola, J., and Netter, T. (1992). AIDS in the World. Harvard University, Cambridge, MA.Google Scholar
  53. Maslow, C. B., Friedman, S. R., Perlis, T. E., Rockwell, R., and Des Jarlais, D. C. (2002). Changes in HIV seroprevalence and related behaviors among male injection drug users who do and do not have sex with men: New York City, 1990–1999. American Journal of Public Health 92(3), pp. 382–384.PubMedCrossRefGoogle Scholar
  54. Metzger, D., Woody, G., McLellan, A., O’Brien, C., Druley, P., Navaline, H., DePhilippis, D., Stolley, P., and Abrutyn, E. (1993). HIV seroconversion among IDUs in and out-of-treatment: An 18-month prospective follow-up. AIDS 6(9), pp. 1049–1056.Google Scholar
  55. Nelson, K., Galai, N., Safaeian, M., Strathdee, S., Celentano, D., and Vlahov, D. (2002). Temporal trends in the incidence of human immunodeficiency virus infection and risk behavior among injection drug users in Baltimore, Maryland, 1988–1998. American Journal of Epidemiology 156(7), pp. 641–653.PubMedCrossRefGoogle Scholar
  56. National Institutes of Health. (1997). Proceedings on the NIH Consensus Development Conference on Interventions to Prevent HIV Risk Behaviors. Paper presented at the Proceedings on the NIH Consensus Development on Interventions to Prevent HIV Risk Behaviors, Bethesda, MD.Google Scholar
  57. Normand, J., Vlahov, D., and Moses, L. E. (Eds.). (1995). Preventing HIV Transmission: The Role of Sterile Needles and Bleach. National Academy Press/National Research Council/Institute of Medicine, Washington, D.C.Google Scholar
  58. O’Keefe, E., Kaplan, E., and Khoshnood, K. (1991). Preliminary Report: City of New Haven Needle Exchange Program: Office of Mayor John C. Daniels, New Haven, CT.Google Scholar
  59. Ostrow, D. G. (1989). AIDS prevention through effective education. Daedalus 118, pp. 229–254.Google Scholar
  60. Perez, K., Rodes, A., Merona, M., and Casabona, J. (2002). Behavioural surveillance among intravenous drug users (IDUs) out-of-treatment in Barcelona (Spain), 1993–2000. Paper presented at the Fourteenth International AIDS Conference, Barcelona, Spain.Google Scholar
  61. Quan, V. M., Steketee, R. W., Valleroy, L., Weinstock, H., Karon, J., and Janssen, R. (2002). HIV incidence in the United States, 1978–1999. Journal of Acquired Immune Deficiency Syndrome 31, pp.188–201.Google Scholar
  62. Robertson, R. (Ed.). (1998). Management of Drug Users in the Community: A Practical Handbook, Oxford University Press Inc., New York.Google Scholar
  63. Saidel, T. J., Des Jarlais, D. C., Peerapatanapokin, W., Dorabjee, J., Siddharth Singh, S., and Brown, T. (in press). Potential impact of HIV among IDUs on heterosexual transmission in Asian settings: The Asian epidemic model. International Journal of Drug Policy.Google Scholar
  64. Selwyn, P., Feiner, C., Cox, C., Lipshutz, C., and Cohen, R. (1987). Knowledge about AIDS and high-risk behavior among intravenous drug abusers in New York City. AIDS 1, pp. 247–254.PubMedGoogle Scholar
  65. Sherman, S. G., and Latkin, C. A. (2002). Drug users’ involvement in the drug economy: implications for harm reduction and HIV prevention programs. Journal of Urban Health 79, pp. 266–277.PubMedGoogle Scholar
  66. Spittal, P. M., Craib, K. J., Wood, E., Laliberte, N., Li, K., Tyndall, M.W., O’Shaughnessy, M. V., and Schechter, M. T. (2002). Risk factors for elevated HIV incidence rates among female injection drug users in Vancouver. Canadian Medical Association Journal 166(7), pp. 894–899.PubMedGoogle Scholar
  67. Stimson, G. V. (1995). AIDS and injecting drug use in the United Kingdom, 1987–1993: the policy response and the prevention of the epidemic. Social Science and Medicine 41(5), pp. 699–716.PubMedCrossRefGoogle Scholar
  68. Stimson, G.V., Des Jarlais, D. C., and Ball, A. (Eds.). (1998). Drug Injecting and HIV Infection: Global Dimensions and Local Responses. UCL Press, London.Google Scholar
  69. Stimson, G., Aceijas, C., Hickman, M., Dehne, K., and Rhodes, T. (2004). Global Estimate of Injecting Drug Use. Paper presented at the International Conference on the Reduction of Drug Use Related Harm, Melbourne, Australia.Google Scholar
  70. Stolte, I. G., Dukers, N. H., de Wit, J. B., Fennema, J. S., and Coutinho, R. A. (2000). Increase in sexually transmitted infections among homosexual men in Amsterdam in relation to HAART. Sex Transmitted Infections 77, pp. 184–186.CrossRefGoogle Scholar
  71. Strathdee, S. A., van Ameijden, E. J. C., Mesquita, Wodak, A., Rana, S., and Vlahov, D. (1998). Can HIV epidemics among injection drug users be prevented? AIDS 12(suppl A), pp. 571–579.Google Scholar
  72. Thompson, P. I., Jones, T. S., Cahill, K., and Medina, V. (1990). Promoting HIV Prevention Outreach Activities Via Community-Based Organizations. Paper presented at the Sixth International Conference on AIDS, San Francisco, CA.Google Scholar
  73. UNAIDS/ WHO. (2003). AIDS Epidemic Update. Joint United Nations Programme on HIV/AIDS (UNAIDS), Geneva.Google Scholar
  74. van Ameijden, E., and Coutinho, R. (1998). Maximum impact of HIV prevention measures targeted at injecting drug users. AIDS 12(6), pp. 625–634.PubMedGoogle Scholar
  75. Vanichseni, S., Des Jarlais, D. C., Choopanya, K., Friedmann, P., Wenston, J., Sonchai, W., Sotheran, J. L., Raktham, S., Carballo, M., and Friedman, S. R. (1993). Condom use with primary partners among injecting drug users in Bangkok, Thailand and New York City, United States. AIDS 7, pp. 887–891.PubMedGoogle Scholar
  76. Vanichseni, S., Choopanya, K., Des Jarlais, D. C., Sakuntanaga, P., Kityaporn, D., Sujarita, S., Raktham, S., Hiranrus, K., Wasi, W., Mock, P. A., and Mastro, T. D. (2002). HIV among Injecting Drug Users in Bangkok: The First Decade. International Journal of Drug Policy 13, pp. 39–44.CrossRefGoogle Scholar
  77. Wiebel, W., Chene, D., & Johnson, W. (1990). Adoption of Bleach Use in a Cohort of Street Intravenous Drug Users in Chicago. Paper presented at the Sixth International Conference on AIDS, San Francisco, CA.Google Scholar
  78. Wiebel, W. (1996). Ethnographic contributions to AID intervention strategies. In: Rhodes, T. and Hartnoll, R. (Eds.), AIDS, Drugs and Prevention: Perspectives on Individual and Community Action, Routledge, New York, pp. 186–200.Google Scholar
  79. Wodak, A., and Lurie, P. (1996). A tale of two countries: Attempts to control HIV among injecting drug users in Australia and the United States. Journal of Drug Issues 27(1), pp. 117–134.Google Scholar
  80. Wright, N., Vanichseni, S., Akarasewi, P., Wasi, C., and Choopanya, K. (1994). Was the 1988 HIV epidemic among Bangkok’s injecting drug users a common source outbreak? AIDS 8, pp. 529–532.PubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, Inc. 2005

Authors and Affiliations

  • Don C. Des Jarlais
    • 1
  • Holly Hagan
    • 2
  • Samuel R. Friedman
    • 2
  1. 1.Beth Israel Medical CenterNew York City
  2. 2.National Development and Research Institutes (NDRI)New York City

Personalised recommendations